Review





Similar Products

95
Elabscience Biotechnology anti mouse cd86 apc antibody
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Anti Mouse Cd86 Apc Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/pmc13769535-148-11-14
Average 95 stars, based on 1 article reviews
anti mouse cd86 apc antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

91
Biogems International anti mouse cd86 apc
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Anti Mouse Cd86 Apc, supplied by Biogems International, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/Anti-Mouse+CD86+(B7-2)+APC/pm42892647-195-30-33
Average 91 stars, based on 1 article reviews
anti mouse cd86 apc - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

95
Elabscience Biotechnology anticd86 apc
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Anticd86 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/pm42879894-211-25-26
Average 95 stars, based on 1 article reviews
anticd86 apc - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Elabscience Biotechnology flow cytometry
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Flow Cytometry, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/pmc13634475-266-4-12
Average 95 stars, based on 1 article reviews
flow cytometry - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Elabscience Biotechnology cd86 apc
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Cd86 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/10__2147_slash_jir__s603120-54-8-16
Average 95 stars, based on 1 article reviews
cd86 apc - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Cytek Biosciences apc rat anti mouse cd86 gl1
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Apc Rat Anti Mouse Cd86 Gl1, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86/pm42813432-236-9-16
Average 93 stars, based on 1 article reviews
apc rat anti mouse cd86 gl1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Elabscience Biotechnology apc conjugated cd86 antibodies
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Apc Conjugated Cd86 Antibodies, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/pm42849374-156-24-27
Average 95 stars, based on 1 article reviews
apc conjugated cd86 antibodies - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Elabscience Biotechnology apc anti mouse cd86
TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.
Apc Anti Mouse Cd86, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/apc+anti+mouse+cd86+antibodies/APC+Anti-Mouse+CD86+Antibody/pm42790655-182-0-4
Average 95 stars, based on 1 article reviews
apc anti mouse cd86 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.

Journal: Materials Today Bio

Article Title: Retinal neuroprotection and microglia M1/M2 polarization modulation of triamcinolone acetonide and basic fibroblast growth factor co-delivered in liposomes after optic nerve injury

doi: 10.1016/j.mtbio.2026.103816

Figure Lengend Snippet: TA/bFGF@Lipo treatment promoted LPS-primed BV2 microglia M1/M2 shift. (A) qRT-PCR of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (B, D) Western blotting and quantification of BV2 microglia M1/M2 markers after LPS and liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (C) Flow cytometry analysis of BV2 microglia M1/M2 markers after LPS and liposomes treatment. (E) Schematic of BV2 microglia M1/M2 shift after liposomes treatment.

Article Snippet: After washing with staining buffer, the cells were incubated with an anti-mouse CD86-APC antibody (Elabscience, Wuhan, China) for 20 min at room temperature.

Techniques: Quantitative RT-PCR, Liposomes, Western Blot, Flow Cytometry, Analysis

TA/bFGF@Lipo treatment promoted microglia M1/M2 shift in the retina 7 days after ONC. (A) Representative immunofluorescence images of Iba1 (green), CD86 (red) and DAPI (blue) of retinas 7 days after ONC. Scale bar: 50 μm. (B) Representative immunofluorescence images of Iba1 (green), Arg-1 (red) and DAPI (blue) of retinas 7 days after ONC. Scale bar: 50 μm. (C) Semi-quantitative analysis of the density and relative fluorescence intensity of CD86 and Arg-1 according to immunofluorescence images A and B. Data are represented as mean ± SD (n = 3 retinas per group, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, *** for p < 0.001, and **** for p < 0.0001.

Journal: Materials Today Bio

Article Title: Retinal neuroprotection and microglia M1/M2 polarization modulation of triamcinolone acetonide and basic fibroblast growth factor co-delivered in liposomes after optic nerve injury

doi: 10.1016/j.mtbio.2026.103816

Figure Lengend Snippet: TA/bFGF@Lipo treatment promoted microglia M1/M2 shift in the retina 7 days after ONC. (A) Representative immunofluorescence images of Iba1 (green), CD86 (red) and DAPI (blue) of retinas 7 days after ONC. Scale bar: 50 μm. (B) Representative immunofluorescence images of Iba1 (green), Arg-1 (red) and DAPI (blue) of retinas 7 days after ONC. Scale bar: 50 μm. (C) Semi-quantitative analysis of the density and relative fluorescence intensity of CD86 and Arg-1 according to immunofluorescence images A and B. Data are represented as mean ± SD (n = 3 retinas per group, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, *** for p < 0.001, and **** for p < 0.0001.

Article Snippet: After washing with staining buffer, the cells were incubated with an anti-mouse CD86-APC antibody (Elabscience, Wuhan, China) for 20 min at room temperature.

Techniques: Immunofluorescence, Analysis, Fluorescence

TIMP1 expression in the retina was promoted by TA/bFGF@Lipo and was related with microglia polarization. (A) Venn diagram of the numbers of DEGs in the four comparison sets. (B, C) Western blotting and quantification of TIMP1 in the retina 7 days after liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, and **** for p < 0.0001. (D) KEGG pathway enrichment results of Timp1 -related DEGs. (E) Pearson correlation analysis between Timp1 and several markers of microglia. (F) qRT-PCR of BV2 microglia M1/M2 biomarkers after LPS and gradient concentrations of rmTIMP1 treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (G, H) Western blotting and quantification of BV2 microglia M1/M2 markers proteins after LPS and gradient concentrations of rmTIMP1 treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001.

Journal: Materials Today Bio

Article Title: Retinal neuroprotection and microglia M1/M2 polarization modulation of triamcinolone acetonide and basic fibroblast growth factor co-delivered in liposomes after optic nerve injury

doi: 10.1016/j.mtbio.2026.103816

Figure Lengend Snippet: TIMP1 expression in the retina was promoted by TA/bFGF@Lipo and was related with microglia polarization. (A) Venn diagram of the numbers of DEGs in the four comparison sets. (B, C) Western blotting and quantification of TIMP1 in the retina 7 days after liposomes treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, and **** for p < 0.0001. (D) KEGG pathway enrichment results of Timp1 -related DEGs. (E) Pearson correlation analysis between Timp1 and several markers of microglia. (F) qRT-PCR of BV2 microglia M1/M2 biomarkers after LPS and gradient concentrations of rmTIMP1 treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001. (G, H) Western blotting and quantification of BV2 microglia M1/M2 markers proteins after LPS and gradient concentrations of rmTIMP1 treatment. Data are represented as mean ± SD (n = 3 independent experiments, one-way ANOVA, Dunnett's test). Non-significant (ns) for p > 0.05, * for p < 0.05, ** for p < 0.01, *** for p < 0.001, and **** for p < 0.0001.

Article Snippet: After washing with staining buffer, the cells were incubated with an anti-mouse CD86-APC antibody (Elabscience, Wuhan, China) for 20 min at room temperature.

Techniques: Expressing, Comparison, Western Blot, Liposomes, Analysis, Quantitative RT-PCR

TIMP1 knockdown by AAV2-shTIMP1 in the retina inhibited TA/bFGF@Lipo's promotion of RGCs survival and microglia M2 polarization. (A) Schematic of TIMP1 knockdown by AAV2-shTIMP1 in the retina. (B) Representative fluorescence images of Rbpms (green) and DAPI (blue) of retinas on 7 dpi when TIMP1 was knockdown. GCL: Ganglion Cell Layer; INL: Inner Nuclear Layer; ONL: Outer Nuclear Layer; RPE: Retinal Pigment Epithelium. Scale bar: 50 μm. (C) Representative immunofluorescence images of Iba1 (green), CD86 (red) and DAPI (blue) of retinas on 7 dpi with or without TA/bFGF@Lipo + AAV-shTIMP1 treatment. Scale bar: 50 μm. (D) Representative immunofluorescence images of Iba1 (green), Arg-1 (red) and DAPI (blue) of retinas on 7 dpi with or without TA/bFGF@Lipo + AAV-shTIMP1 treatment. Scale bar: 50 μm.

Journal: Materials Today Bio

Article Title: Retinal neuroprotection and microglia M1/M2 polarization modulation of triamcinolone acetonide and basic fibroblast growth factor co-delivered in liposomes after optic nerve injury

doi: 10.1016/j.mtbio.2026.103816

Figure Lengend Snippet: TIMP1 knockdown by AAV2-shTIMP1 in the retina inhibited TA/bFGF@Lipo's promotion of RGCs survival and microglia M2 polarization. (A) Schematic of TIMP1 knockdown by AAV2-shTIMP1 in the retina. (B) Representative fluorescence images of Rbpms (green) and DAPI (blue) of retinas on 7 dpi when TIMP1 was knockdown. GCL: Ganglion Cell Layer; INL: Inner Nuclear Layer; ONL: Outer Nuclear Layer; RPE: Retinal Pigment Epithelium. Scale bar: 50 μm. (C) Representative immunofluorescence images of Iba1 (green), CD86 (red) and DAPI (blue) of retinas on 7 dpi with or without TA/bFGF@Lipo + AAV-shTIMP1 treatment. Scale bar: 50 μm. (D) Representative immunofluorescence images of Iba1 (green), Arg-1 (red) and DAPI (blue) of retinas on 7 dpi with or without TA/bFGF@Lipo + AAV-shTIMP1 treatment. Scale bar: 50 μm.

Article Snippet: After washing with staining buffer, the cells were incubated with an anti-mouse CD86-APC antibody (Elabscience, Wuhan, China) for 20 min at room temperature.

Techniques: Knockdown, Fluorescence, Immunofluorescence, Western Blot